| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1989.7.4.486 |
| P698 | PubMed publication ID | 2647914 |
| P50 | author | Janice P Dutcher | Q90323603 |
| P2093 | author name string | J H Doroshow | |
| K A Margolin | |||
| R I Fisher | |||
| G R Weiss | |||
| M J Hawkins | |||
| M B Atkins | |||
| H S Jaffe | |||
| A A Rayner | |||
| M Roper | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 486-498 | |
| P577 | publication date | 1989-04-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines | |
| P478 | volume | 7 |
| Q49332278 | A Case of Myocarditis and Near-Lethal Arrhythmia Associated With Interleukin-2 Therapy |
| Q47563772 | A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects |
| Q71643806 | A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients |
| Q57749178 | Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2 |
| Q79150748 | Antineoplastic Effects of Partially HLA-Matched Irradiated Blood Mononuclear Cells in Patients With Renal Cell Carcinoma |
| Q35753505 | Application of IL-2 and other cytokines in renal cancer |
| Q38815946 | Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation |
| Q34107958 | Biochemotherapy for melanoma |
| Q44541472 | Bolus Followed by Continuous Infusion Interleukin-2 in Patients with Metastatic Malignant Melanoma and Kidney Cancer Previously Treated with Interleukin-2 |
| Q38313870 | Cancer chemotherapy and cardiac arrhythmias: a review. |
| Q33559591 | Cardiomyopathy associated with high-dose interleukin-2 therapy |
| Q41689551 | Cardiovascular toxicity with cancer chemotherapy |
| Q41525667 | Case Report. Colosplenic Fistula in a Patient Treated with Interleukin-2 for Malignant Melanoma |
| Q36589103 | Central Nervous System Toxicity of Biological Response Modifiers |
| Q35580479 | Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors |
| Q46903999 | Chronic interleukin-2 treatment in awake sheep causes minimal or no injury to the lung microvascular barrier |
| Q40953955 | Cisplatin-based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin-12 incubation |
| Q81399311 | Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report |
| Q33355316 | Clinical toxicity of interleukin-2. |
| Q72284657 | Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction |
| Q61911235 | Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma |
| Q40875316 | Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV. |
| Q38267711 | Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders |
| Q36723646 | Cytokines in anticancer therapy |
| Q70599547 | Dissociation of natural killer and lymphocyte-activated killer cell lytic activities in human CD3- large granular lymphocytes |
| Q84627320 | Drug-induced atrial fibrillation |
| Q33415481 | Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program |
| Q68326713 | Ecogramostim and pre-existing autoimmune thyroid disease |
| Q52592617 | Electrophysiologic Toxicity of Chemoradiation. |
| Q39714477 | Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients |
| Q40754856 | Haemodynamic effects of recombinant interleukin-2 administered by constant infusion |
| Q59400683 | High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 |
| Q71015279 | High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience |
| Q80508965 | Homing of radiolabelled recombinant interleukin-2 activated natural killer cells and their efficacy in adoptive immunotherapy against murine fibrosarcoma |
| Q37253572 | Human autologous tumor-specific T cells in malignant melanoma |
| Q35661491 | IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells. |
| Q90623091 | Immunotherapy Against Gliomas: is the Breakthrough Near? |
| Q35157638 | Immunotherapy for renal cell carcinoma |
| Q40539148 | Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment |
| Q71931101 | Immunotherapy of malignant melanoma |
| Q37463892 | Immunotherapy of metastatic renal cell carcinoma |
| Q47287952 | Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry |
| Q39232767 | Interleukin-2 in cancer treatment: disappointing or (still) promising? A review |
| Q34306890 | Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer |
| Q38996288 | Irradiated mononuclear cells express significant in vitro cytotoxic activity: promise for in vivo clinical efficacy of irradiated mismatched donor lymphocytes infusion. |
| Q34579252 | Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines |
| Q36663524 | Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy |
| Q44312624 | Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution |
| Q33694402 | Making the transition from hospital to home: caring for the newly diagnosed child with cancer |
| Q40948910 | Medical treatment of advanced renal cell carcinoma: present options and future directions |
| Q53393882 | Microscopic Venous Infiltration As Predictor Of Relapse In Renal Cell Carcinoma |
| Q38180319 | Mitigating the toxic effects of anticancer immunotherapy |
| Q36134535 | NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice |
| Q41051859 | Nursing management of patients receiving biological therapy |
| Q40755408 | Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects |
| Q40707862 | Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancer |
| Q36138945 | Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2. |
| Q37686896 | Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma |
| Q45770715 | Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. |
| Q40482190 | Pure Red Cell Aplasia Following Interleukin-2 Therapy. |
| Q37803895 | Rationale for immunotherapy of renal cell carcinoma |
| Q71900148 | Recombinant interleukin-2 acts like a class I antiarrhythmic drug on human cardiac sodium channels |
| Q45106794 | Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II study |
| Q70501182 | Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy |
| Q36231087 | Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF |
| Q35823805 | Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2 |
| Q28067610 | Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date |
| Q35979169 | Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. |
| Q40684209 | Successful treatment of retinoic acid syndrome with high‐dose dexamethasone pulse therapy in a child with acute promyelocytic leukemia treated with ATRA |
| Q39264898 | Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities |
| Q34569970 | The biological treatment of renal-cell carcinoma and melanoma |
| Q35044419 | The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma |
| Q37427683 | The immunotherapy of human cancer with interleukin 2: present status and future directions |
| Q37047969 | Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma |
| Q36718958 | Update on the application of interleukin-2 in the treatment of renal cell carcinoma |
| Q41664945 | Vascular leak syndrome: a side effect of immunotherapy |
Search more.